ATE448312T1 - Leitsequenzen zur verwendung bei der produktion von proteinen - Google Patents

Leitsequenzen zur verwendung bei der produktion von proteinen

Info

Publication number
ATE448312T1
ATE448312T1 AT04787205T AT04787205T ATE448312T1 AT E448312 T1 ATE448312 T1 AT E448312T1 AT 04787205 T AT04787205 T AT 04787205T AT 04787205 T AT04787205 T AT 04787205T AT E448312 T1 ATE448312 T1 AT E448312T1
Authority
AT
Austria
Prior art keywords
proteins
production
dna constructs
leader sequences
guide sequences
Prior art date
Application number
AT04787205T
Other languages
English (en)
Inventor
Philippe Dupraz
Michel Kobr
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Application granted granted Critical
Publication of ATE448312T1 publication Critical patent/ATE448312T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT04787205T 2003-09-26 2004-09-24 Leitsequenzen zur verwendung bei der produktion von proteinen ATE448312T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03103580 2003-09-26
US50693903P 2003-09-29 2003-09-29
PCT/EP2004/052302 WO2005030963A1 (en) 2003-09-26 2004-09-24 Leader sequences for use in production of proteins

Publications (1)

Publication Number Publication Date
ATE448312T1 true ATE448312T1 (de) 2009-11-15

Family

ID=34924107

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04787205T ATE448312T1 (de) 2003-09-26 2004-09-24 Leitsequenzen zur verwendung bei der produktion von proteinen

Country Status (8)

Country Link
US (1) US20070141666A1 (de)
EP (1) EP1670918B1 (de)
JP (1) JP4809227B2 (de)
AT (1) ATE448312T1 (de)
AU (1) AU2004276522B2 (de)
CA (1) CA2537340A1 (de)
ES (1) ES2333724T3 (de)
WO (1) WO2005030963A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2439014T3 (es) * 1998-02-20 2014-01-21 The University Of Miami Complejo de péptido antigénico-proteína de choque térmico modificada
JP4467815B2 (ja) * 2001-02-26 2010-05-26 富士通マイクロエレクトロニクス株式会社 不揮発性半導体メモリの読み出し動作方法および不揮発性半導体メモリ
EP2257301B1 (de) 2008-03-03 2014-01-22 The University of Miami Auf allogenen krebszellen basierende immuntherapie
AU2009226077B2 (en) * 2008-03-20 2012-04-19 University Of Miami Heat shock protein gp96 vaccination and methods of using same
WO2010060026A1 (en) * 2008-11-21 2010-05-27 University Of Miami Hiv/siv vaccines for the generation of mucosal and systemic immunity
HK1222331A1 (zh) 2013-03-12 2017-06-30 通用医疗公司 修饰的缪勒抑制物质(mis)蛋白及其用於疾病治疗的用途
EP3046582A4 (de) 2013-09-20 2017-05-10 The General Hospital Corporation Verwendung von modifizierten müllerschen hemmstoff (mis)-proteinen zur behandlung von neurodegenerativen erkrankungen
US11135269B2 (en) 2013-12-11 2021-10-05 The General Hospital Corporation Use of mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservation
KR20170109582A (ko) 2015-02-06 2017-09-29 히트 바이오로직스, 인코퍼레이티드 벡터 공동 발현 백신 및 공동 자극 분자
EP3443001B1 (de) 2016-04-11 2025-04-30 Obsidian Therapeutics, Inc. Regulierte bioschaltkreissysteme
CA3040123A1 (en) 2016-10-11 2018-04-19 University Of Miami Vectors and vaccine cells for immunity against zika virus
WO2018112168A1 (en) 2016-12-14 2018-06-21 The General Hospital Corporation Mullerian inhibiting substance (mis) proteins for ovarian and uterine oncoprotection, and ovarian reserve and uterine preservation
CN110831961B (zh) 2017-03-03 2024-01-02 黑曜石疗法公司 用于免疫疗法的cd19组合物和方法
US11548930B2 (en) 2017-04-04 2023-01-10 Heat Biologics, Inc. Intratumoral vaccination
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2020086742A1 (en) 2018-10-24 2020-04-30 Obsidian Therapeutics, Inc. Er tunable protein regulation
KR20210149251A (ko) 2019-03-08 2021-12-08 옵시디안 테라퓨틱스, 인크. 조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법
JP2022537670A (ja) 2019-06-12 2022-08-29 オブシディアン セラピューティクス， インコーポレイテッド Ｃａ２の組成物および調整可能な制御方法
WO2020252404A1 (en) 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
AU2022205679A1 (en) 2021-01-08 2023-07-06 Strand Therapeutics Inc. Expression constructs and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8723662D0 (en) 1987-10-08 1987-11-11 British Bio Technology Synthetic gene
KR19990076877A (ko) 1995-12-29 1999-10-25 스티븐 베네티아너 비트로넥틴 수용체 길항제
AU763513B2 (en) * 1998-04-16 2003-07-24 Genentech Inc. Secretion of glycosylated proteins using a tissue plasminogen activator pro-sequence
ATE323766T1 (de) 1999-02-12 2006-05-15 Amgen Inc Glykosylierte leptinzusammensetzungen und zugehörige verfahren
US6420345B1 (en) * 1999-03-01 2002-07-16 Cell Genesys, Inc. Methods and reagents for inhibiting angiogenesis
IL140110A0 (en) 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
US20040038304A1 (en) * 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
US7696322B2 (en) * 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies

Also Published As

Publication number Publication date
JP4809227B2 (ja) 2011-11-09
CA2537340A1 (en) 2005-04-07
WO2005030963A1 (en) 2005-04-07
AU2004276522A1 (en) 2005-04-07
AU2004276522B2 (en) 2010-12-02
EP1670918B1 (de) 2009-11-11
EP1670918A1 (de) 2006-06-21
US20070141666A1 (en) 2007-06-21
JP2007506420A (ja) 2007-03-22
ES2333724T3 (es) 2010-02-26

Similar Documents

Publication Publication Date Title
ATE437652T1 (de) Verwendung von hmgb1 zur aktivierung dendritischer zellen
ATE519847T1 (de) Il-17-homologe polypeptide und ihre therapeutische verwendung
DE60325892D1 (de) Stellungs- und verwendungsverfahren
ATE457355T1 (de) Verfahren und dna-konstrukte zur produktion von polypeptiden mit hoher ausbeute
DE602006011574D1 (de) Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung
ATE447583T1 (de) Polypeptide und dafür kodierende nukleinsäure
ATE414775T1 (de) Polypeptide mit prolyldipeptidylaminopeptidase- aktivität und dafür kodierende nukleinsäuren
ATE424457T1 (de) Menschliche stra6 polypeptide
KR100468977B1 (ko) 분비 및 막횡단 폴리펩티드, 및 이를 코딩하는 핵산
CY1118782T1 (el) Επιλογη κυτταρων που εκφραζουν ετερομερη πολυπεπτιδια
DK1616878T3 (da) Udskilte og membranspændende polypeptider samt nukleinsyrer kodende for disse
DE60214127D1 (de) Hybridomzelllinie g250 und deren verwendung zur herstellung monoklonaler antikörper
DE60111783D1 (de) Verfahren zur herstellung und reinigung von sekretierten proteinen und herstellung von protein-arrays
ATE513033T1 (de) Expression von proteinen in aus nabelschnurblut gewonnenen endothelzellen
ATE374825T1 (de) Verwendung von caspasen zur herstellung von reifen rekombinanten fusionsproteinen
PT1366161E (pt) Anticorpo anatagonista anti-pro842
NO20061858L (no) Ledersekvenser for anvendelse ved produksjon av proteiner
ATE335005T1 (de) Menschliches protein mit in vitro antiproliferativer aktivität.
ATE386129T1 (de) Produktion eukaryontischer proteine und nukleinsäuremoleküle in c. elegans
DE69937756D1 (de) Menschliches Prostasin-ähnliches Protein und dafür kodierende Nukleinsäure
DE69939227D1 (de) Menschliches A33-Antigen-ähnliches Protein und dafür kodierende Nukleinsäure
DE60043258D1 (de) Menschliches suppressor von fused
ATE447026T1 (de) Ausgeschiedene und transmembrane polypeptide und dafür kodierende nukleinsäure
DK1241183T3 (da) Humant HCAR-agtig protein og nucleinsyrer kodende derfor
DE60038986D1 (de) Ausgeschiedene und Transmembranpolypeptide und dafür kodierende Nukleinsäure

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties